EGFR and cancer: In addition, chemotherapy weakens patients' immune system which may interfere with the inflammatory phase of wound healing and increase the possibility of wound infections.74, 75 Targeted therapeutics such as epidermal growth factor receptor (EGFR) or VEGF inhibitors should be less toxic to normal cells, but their therapeutic targets involved in cancer growth also participate in wound healing, so the use of these therapeutics is associated with adverse reactions, including skin toxicity.76